ICU, intensive care, TDM, therapeutic drug monitoring, beta-lactams, anitbiotics, cephalosporins, fluroquinolones, MIC, PK/PD, pharmacokinetcs, pharmacodynamics
Conditions
Interventions
There is no intervention in this study that may affect patient treatment.
Sponsors
Erasmus University Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: - Written informed consent has been obtained from the patient or their legally authorized representative. - Receiving intravenous antibiotic therapy of the target drugs. - Suitable intravenous/intra-arterial access to facilitate sample collection. - Treatment should be aimed for at least at 3 days. - Bacterial isolates sample are obtainable before start of the target drugs.
Exclusion criteria
Exclusion criteria: - Consent not obtained. - <18 years of age. - Antibiotic cessation within 72h of identification of expected sampling. - Medium care and burn wound patients admitted to the ICU.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| to document whether empirical antibiotic dosing regimens of these antibiotics achieve defined therapeutic target concentrations in ICU patients.: Achievement of the PK/PD targets. PK/PD indices are calculated for each individual patient. | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of observed PK/PD indices of the individual antibiotics with the length of ICU stay and sickness severity scores in ICU patients. | — |
Contacts
Public ContactA Abdulla
Erasmus Medical Centre - Department of Hospital Pharmacy
Outcome results
None listed